Green Thumb Industries (GTBIF) Cash from Financing Activities (2019 - 2026)
Green Thumb Industries (GTBIF) posted Cash from Financing Activities of $5.7 million for Q1 2026, up 127.02% on a QoQ basis from -$21.1 million in Q4 2025, and up 219.97% year-over-year from $1.8 million in Q1 2025.
Green Thumb Industries (GTBIF) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Green Thumb Industries' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 219.97% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.5 million (up 54.46% YoY) and the FY2025 annual result came in at -$50.9 million, up 46.71% from the prior year.
- Cash from Financing Activities was $5.7 million for Q1 2026 at Green Thumb Industries, up from -$21.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $18.9 million in Q4 2022 and bottomed at -$51.1 million in Q3 2024.
- A 5-year average of -$8.5 million and a median of -$5.8 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 10420.0% — and 2024, when it sank 8320.59%.
- Green Thumb Industries' Cash from Financing Activities stood at $18.9 million in 2022, then slumped by 130.97% to -$5.8 million in 2023, then sank by 57.38% to -$9.2 million in 2024, then slumped by 129.8% to -$21.1 million in 2025, then jumped by 127.02% to $5.7 million in 2026.
- Business Quant data shows GTBIF's Cash from Financing Activities at $5.7 million in Q1 2026, -$21.1 million in Q4 2025, and -$2.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | 5.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.71 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Dec 31, 2025 | -21.12 Mn |
| Dec 31, 2025 | -21.12 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Jun 30, 2025 | -22.43 Mn |
| Jun 30, 2025 | -22.43 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -51.06 Mn |
| Sep 30, 2024 | -51.06 Mn |
| Jun 30, 2024 | -23.89 Mn |
| Jun 30, 2024 | -23.89 Mn |
| Mar 31, 2024 | -11.45 Mn |
| Mar 31, 2024 | -11.45 Mn |
| Dec 31, 2023 | -5.84 Mn |
| Dec 31, 2023 | -5.84 Mn |